Sartorius AG (FRA:SRT) LT-Debt-to-Total-Asset : 0.46 (As of Mar. 2024)

View and export this data going back to 1990. Start your Free Trial

What is Sartorius AG LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Sartorius AG's long-term debt to total assests ratio for the quarter that ended in Mar. 2024 was 0.46.

Sartorius AG's long-term debt to total assets ratio increased from Mar. 2023 (0.32) to Mar. 2024 (0.46). It may suggest that Sartorius AG is progressively becoming more dependent on debt to grow their business.

Sartorius AG LT-Debt-to-Total-Asset Historical Data

The historical data trend for Sartorius AG's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sartorius AG LT-Debt-to-Total-Asset Chart

Sartorius AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.31

0.42

0.31

0.29

0.52

Sartorius AG Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.32	0.32	0.51	0.52	0.46

Sartorius AG LT-Debt-to-Total-Asset Calculation

Sartorius AG's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	5023.3	/	9755.3
	=	0.51

Sartorius AG's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (Q: Mar. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2024 )	/	Total Assets (Q: Mar. 2024 )
	=	4863	/	10627.8
	=	0.46

Sartorius AG (FRA:SRT) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Sartorius AG LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Sartorius AG's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Sartorius AG (FRA:SRT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sartorius AG (FRA:SRT) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

SOAGY:USA SSSGY:USA SUVPF:USA SARTF:USA 1SRT3:Italy SRT3d:UK 0NIR:UK SRT3:Germany SRT3:Austria

Address

Otto-Brenner-Strasse 20, Gottingen, NI, DEU, 37079

Website

https://www.sartorius.com

Sartorius AG is a leading provider of bioprocessing solutions. Its Bioprocess division sells equipment and consumables for upstream and downstream manufacturing of biologic drugs, and has a focus on single-use technology, or SUT. Its Lab Products and Services division offers a wide range of products for lab use, including scales, pipettes, and filtration equipment. As of 2022, the Bioprocess and LPS divisions contributed 80% and 20% of revenue, respectively. Bioprocess is housed in its subsidiary Sartorius Stedim Biotech, of which Sartorius AG has a 74% ownership and 85% voting control. The business is geographically diverse, with revenue across Europe, the Middle East, and Africa (37% of 2022 sales), the Americas (37%), and Asia-Pacific (26%). We estimate China revenue to be around 10%.